Sanofi SA (ADR) (SNY), Merck & Co., Inc. (MRK): Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

Page 1 of 2

Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk of this disease, the incidence of which has grown 30-fold during the last 50 years.

Poised for gains from brewing remedies

The good news is, in about two years, the world will possibly have its first dengue vaccine. The big pharma Sanofi SA (ADR) (NYSE:SNY) is now conducting two late-stage human testings involving some 45,000 participants in Asia and Latin America. The results are expected either late 2013 or in 2014.

In addition, there are other vaccine types in the most advanced stage of development. Phase I trial, for instance, has been completed on a vaccine developed by the privately held Hawaii Biotech. New Jersey-based Merck & Co., Inc. (NYSE:MRK) now owns the rights on this vaccine, which it acquired in 2010.

The U.K.-based GlaxoSmithKline plc (ADR) (NYSE:GSKis also in pursuit of a vaccine type similar to Sanofi SA (ADR) (NYSE:SNY)’s. It has conducted several clinical studies on this vaccine, including those done in the U.S., Puerto Rico, and Thailand. The company has also partnered with the Fiocruz, a Brazilian foundation, for the development and manufacturing of the vaccine for dengue in Brazil where this disease is a major health concern.

A prop-up for a weak quarter

Sanofi SA (ADR) (NYSE:SNY)An advance in Glaxo’s pursuit of a dengue vaccine should provide tailwinds to the company, which has been reaping some negative market sentiment due to a recent bribery scandal in China and generics eating into its market share. Reporting a 4% core EPS gain on 2% sales growth in the second quarter, Glaxo acknowledged that the result of the bribery investigation is likely to impact its subsequent performance in China.

Certainly, a step up of the dengue vaccine in Merck & Co., Inc. (NYSE:MRK)’s pipeline can also burnish this company’s allure among investors who were turned off recently by a staggering 48% drop in company earnings and 10% decline in revenue during the second quarter primarily due to competition from generics.

Like Glaxo and Merck & Co., Inc. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY) has also been feeling the pinch of generic competition. In the second quarter, sales lost to generics resulted in a 6.3% decline in Sanofi’s total sales and an 18.5% drop in business EPS.

Despite their recent weak results, a strong rebound from this triumvirate can’t be discounted. Besides their dengune vaccines under development, they also have other drugs in the pipeline which are potential earning catalysts.

For the near term, Merck & Co., Inc. (NYSE:MRK) hopes to draw strength from about 40 drugs in its pipeline, out of which six are close to market launch. Just this July, the U.S. FDA has accepted the new drug application for Merck’s anti thrombotic candidate, vorapaxar, for standard testing. Speculations are also rife that the company is eyeing to bolster its product entries in the lucrative oncology medicines through an acquisition.

GlaxoSmithKline plc (ADR) (NYSE:GSK), for its part, flaunts new respiratory products coming onto the market, one of which is the recently FDA-approved Breo Ellipta, which analysts believe to have a peak potential of $1.3 billion sales in the U.S. alone. Likewise potent in earnings possibility is the company’s protein-based therapy, ofatumumab, for multiple sclerosis, now on Phase II trial.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

The 20 Biggest Contracts in MLB History

The 7 Worst Blown Calls in Sports History

7 Free Ways to Advertise Your Business Online

The 18 Best R&B Songs of the 90’s

The 10 Most Dangerous States to be a Cop

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!